Analysts Set Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Target Price at $7.75

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $7.75.

A number of equities research analysts have commented on the stock. Bank of America cut their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. JMP Securities cut their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a report on Thursday, August 21st. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th.

Insider Activity at Werewolf Therapeutics

In other Werewolf Therapeutics news, major shareholder Ansbert Gadicke sold 83,230 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $0.97, for a total value of $80,733.10. Following the transaction, the insider directly owned 4,784,111 shares in the company, valued at approximately $4,640,587.67. This trade represents a 1.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $0.97, for a total transaction of $80,733.10. Following the transaction, the insider owned 4,784,111 shares in the company, valued at $4,640,587.67. This represents a 1.71% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 5,110,700 shares of company stock worth $5,873,645. 23.60% of the stock is owned by company insiders.

Institutional Trading of Werewolf Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Quadrature Capital Ltd purchased a new stake in Werewolf Therapeutics in the second quarter worth about $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $48,000. Nuveen LLC purchased a new stake in Werewolf Therapeutics in the 1st quarter worth approximately $71,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter worth approximately $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth approximately $92,000. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

HOWL opened at $1.00 on Thursday. The company’s 50-day simple moving average is $1.35 and its two-hundred day simple moving average is $1.33. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The stock has a market capitalization of $48.54 million, a P/E ratio of -0.62 and a beta of 0.74. Werewolf Therapeutics has a 52-week low of $0.60 and a 52-week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts predict that Werewolf Therapeutics will post -1.56 EPS for the current year.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.